A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

Clinical trial NCT04161495 · COMPLETED

Trial details

NCT number: NCT04161495
Sponsor: Bioverativ, a Sanofi company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Factor VIII Deficiency

Start date: 2019-11-19
Primary completion: 2022-02-03
Enrollment: 159

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.